On March 5, Japan unveiled new NHI prices for the FY2024 drug price revision. A Jiho survey found that Tsumura, a specialist in Japanese Kampo herbal medicines, received an astonishing raise of over 24% in its drug prices on a…
HOME > REGULATORY
REGULATORY
- MHLW to Take Strict Action on Bayer after Xarelto Survey Probe
July 19, 2017
- MHLW Panel Agrees to Compile Guidelines to Address Polypharmacy in the Elderly
July 18, 2017
- Gov’t Establishing System to Quickly Provide Unapproved Drugs to Developing Countries, Learning from Inadequate Response to Request for Avigan
July 18, 2017
- Pfizer’s Breast Cancer Med Palbociclib Up for MHLW Panel Review on July 27
July 14, 2017
- Drug Price Cut Only Way to Eke Out FY2018 Funding, though Pharmas Important: Top MD Bureaucrat
July 14, 2017
- MHLW Presents Draft Survey Sheet for “Willing-to-Pay” Costs in “CEA” Scheme: Chuikyo
July 13, 2017
- Chuikyo Starts Debate on Interim Report on CEA, Industry Hearings Slated for Next Meeting
July 13, 2017
- Alminoprofen Reclassified as Class 1 OTC Drug: MHLW
July 13, 2017
- Osaka Prefecture to Conduct Surprise Onsite Inspections of API Manufacturing Facilities in Wake of Acetaminophen Scandal
July 13, 2017
- Retired Vice Minister Happy to See Stage Set for Timely Price Revisions
July 12, 2017
- MHLW to Announce Data Required for Conditional Early Approval
July 12, 2017
- Further Transformation beyond Pricing Overhaul Inevitable: Outgoing MHLW Economic Affairs Chief
July 10, 2017
- Applications for Partial Modification to Suffice to Change Manufacturing Processes for Biopharmaceuticals: MHLW Notification
July 7, 2017
- MHLW to Enhance Awareness about Tougher Controls on Private Importing of Drugs by Doctors
July 7, 2017
- MHLW Floats Standard Processing Time for Cost-Effective Assessments: Chuikyo
July 6, 2017
- Chuikyo Reps Trade Barbs over Timing of Post-“CEA” Price Adjustments
July 6, 2017
- Drugs Containing Codeine to Be Contraindicated in Children Younger than 12: MHLW Notifications
July 6, 2017
- Suzuki Tapped for Newly Created Medical Commissioner Post: MHLW Personnel Reshuffle
July 5, 2017
- Add Sclerosing Cholangitis to ADR List in Opdivo Label: MHLW
July 5, 2017
- MHLW OKs Spinraza, Tenelia-Canaglu Combo, and More
July 4, 2017
ページ
Too often, recruiters are more clear on what a position will “do” rather than what it will “achieve”.Outlining tasks and responsibilities takes priority over goals and impact.But to attract top talent, you need to define and explain what success looks…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…